Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Lidocaine Administration in Thoracoscopic Surgery for Improved Postoperative Pain Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing video-assisted thoracoscopic procedures under general anaesthesia.~* American Society of Anesthesiologists (ASA) physical Status classes I to III~* age ≥ 18 years~* Patient informed consent~Exclusion Criteria:~* Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product~* Contraindications to self-administration of opioids~* Women who are pregnant or breast feeding~* Steroid therapy~* Chronic pain therapy~* Atrioventricular block grade II to III~* Congestive heart failure~* Liver insufficiency~* Known or suspected non-compliance, drug or alcohol abuse~* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia~* Participation in another study with investigational drug within the 30 days preceding and during the present study,~* Enrolment of the investigator, his/her family members, employees and other dependent persons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: ACTIVE_COMPARATOR): perioperative IV administration regimen of lidocaine will be as follows: 1.5 mg/kg IV induction bolus dose (before intubation and at least 30 minutes before incision) followed by continuous infusion of 3.mg/kg/h, until 2 hours after skin closure
- Placebo (Type: PLACEBO_COMPARATOR): perioperative IV administration regimen of placebo solution (NaCl 0,9%) will be as follows: induction bolus (before intubation and at least 30 minutes before incision) followed by continuous infusion of placebo solution (NaCl 0,9%) until 2 hours after skin closure

Based on this trial design, predict the completion outcome and termination type (if applicable).